Clinically significant liver injury in patients treated with natalizumab

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 1028-1035

  Bezabeh, S ^a   Flowers, C M ^a   Kortepeter, C ^a   Avigan, M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA INTERFERON; BILIRUBIN; MYCOPHENOLIC ACID; NATALIZUMAB; PREDNISONE; STEROID; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FATIGUE; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; JAUNDICE; LIVER BIOPSY; LIVER INJURY; MALE; MULTIPLE SCLEROSIS; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; TOXIC HEPATITIS; URINE; CASE REPORT; MIDDLE AGED;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 77950583142     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04262.x     Document Type: Article

References (20)

1. Sandborn WJ, Yendnock TA. Novel approaches to treating inflammatory bowel disease: targeting alpha- 4 intergrin. AM J Gastroenterology 2003 98 : 2372 2382.
2. Available at: http://www.fda.gov/cder/drug/infopage/natalizumab/RiskMAP. pdf. Accessed August 30, 2008.
3. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects abd production problems. JAMA 1993 269 : 2765 2768. (Pubitemid 23154251)
4. Brinker A, Beitz J. Use of a spontaneous adverse drug events database for identification of unanticipated drug benefits. Clin Pharmacol Ther 2002 71 : 99 102. (Pubitemid 34124043)
5. Zimmerman HJ. Drug- induced liver disease. Clin Liver Dis 2000 4 : 73 96.
6. Brinker AD, Wassel RT, Lyndly J, et al. Telithromycin-Associated Hepatotoxicity: clinical Spectrum and Causality Assessment of 42 Cases. Hepatology 2009 49 : 250 257.
7. Benichou C. Criteria of drug-induced liver disorders. Report of an international Consensus Meeting. J Hepatology 1990 11 : 272 276.
8. As part of TOUCH Prescribing Program, Biogen Idec™ submitted natalizumab patient exposure post-marketing data to the FDA.
9. Remicade (infliximab) for IV injection [prescribing information].
10. Humira (adalimumab) [prescribing information].
11. Available at: http://www.fda.gov/cder/foi/label/2005/103780s5062lbl.pdf. Acce-ssed August 30, 2008.
12. Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001 76 : 84 6.
13. Micheal M, Duoux C, Hezode C, et al. Fulminat hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003 30 : 1624 1625. (Pubitemid 36835467)
14. Available at: http://www.fda.gov/cder/foi/label/2006/ 020241SLRs10s21s25s26s27,020764SLRs3s14s18s19s20lbl.pdf
15. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/natalizumab/ H-603-PI-en.pdf. Accessed August 30, 2008.
16. Available at: http://www.fda.gov/ohrms/dockets/ac/07/slides/2007-4313s1- 00-index.htm. Accessed August 30, 2008.
17. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis, Gut 2004 53 : 1363 1365. (Pubitemid 39120128)
18. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002 3 : 333 340. (Pubitemid 34661982)
19. Rosen HR, Martin P. Viral hepatitis in the liver transplant recipient. Infect Dis Clin North Am 2000 14 : 761 784. (Pubitemid 32048437)
20. Lee PC, Hung CJ, Lei HY, Chang TT, Wang JR, Jan MS. Parvovirus B19-related acute hepatitis in an immunosuppressed kidney transplant. Nephrol Dial Transplant 2000 15 : 1486 1488.